If AUVI-Q is Back, Why Can’t I Get One?
As many in our food allergy community know, AUVI-Q auto-injectors made their highly-anticipated return to the epinephrine market on February 14. As part of this return, parent company, kaleo, make a huge splash by offering a number of opportunities to acquire a set of AUVI-Q for $0. In fact, it seems that the majority of auto-injector patients will fit the criteria for this free offer! Of course, not every aspect of the AUVI-Q return has been perfect – most importantly in my mind that these pocket-sized auto-injectors are not readily available in the nation’s major pharmacies. However, kaleo made plans to get around that via a direct-to-consumer delivery program (which also cuts a lot of healthcare system costs out of the process).
The result of this return of AUVI-Q to the market has been tremendous demand, significantly greater than kaleo imagined – so much so that there is now a 4-6 week delay for most patients to receive a set of 2. This delay is expected to be one-time in nature – in other words, by early May, kaleo expects there to be no further delay in receiving AUVI-Q ordered directly from them.
Kudos to kaleo for making senior management available to speak with me on a number of occasions, as well as for releasing a letter from the CEO to the patient community, explaining and apologizing for the delays. (A copy of that letter is published at the end of this blog post.)
So what’s the story behind the story? There seem to have been a confluence of events that led to this temporary delay. Namely,
- For a number of hard-to-predict reasons, demand for AUVI-Q out of the gate was extremely high
- kaleo management underestimated this demand (in fact, demand was roughly 4x kaleo’s best-case plan with sales in the first 10 days exceeding their expectations for February AND March)
- kaleo did not want to run into a big problem Sanofi stumbled on when that company marketed AUVI-Q last time around; namely, overproducing beyond demand to the point that patients were getting auto-injectors with expiration dates as short as 6 months out (versus the 15 month original expiry)
kaleo is quick to point out that this is a temporary problem and that they are well on their way to resolving it. They already have in place plenty of capacity to satisfy the current demand and much, much more (again, holding production back in order to manufacture as close to just-in-time as possible to insure maximum time to expiration). Therefore, they have already started ramping up production while taking some necessary short-term measures, including the following:
- Letting patients know that new scripts may take up to 4-6 weeks to fill and ship
- Only allowing patients to only order one set of AUVI-Q at a time, temporarily removing the option they offer to order two sets at once
- Asking doctors to encourage patients with currently unexpired autoinjectors (of another brand) to hold off ordering AUVI-Q
- Attempting to prioritize (to the best of their ability) those patients currently without epinephrine auto-injector options
The bottom line is that demand for AUVI-Q is booming and management is being as expeditious as possible to satisfy that demand. Short-term stumbles like this shouldn’t be terribly surprising given the uncertainties of a major re-launch such as this, combined with the changing landscape of the epinephrine auto-injector market.
I feel it only fair to point out that there have been other criticisms of kaleo on social media that are similarly reasonable mistakes from a re-launch, such as people receiving a bill in their package (that shouldn’t happen and should NOT be paid, according to my kaleo contact) or packages being received cold (I confess that mine was a little chilly), and other criticisms that go beyond what I would consider temporary, such as insurance saying they won’t cover AUVI-Q (call 877-30-AUVIQ, as you should still be able to receive free sets) and patients having to call kaleo to receive each new set of AUVI-Q, even if multiples are prescribed and ordered at once.
That all said, I can’t help but be impressed by the incredible level of demand for the re-launched AUVI-Q. It seems that not only are prior patients willing to forgive past mistakes (that led to a full AUVI-Q recall), but in actuality even more patients are seeking to make AUVI-Q their go-to auto-injector. A result of Mylan’s (maker of Epi-Pen) missteps with the community? Fallout from CVS and others switching Epi-Pen prescriptions to generics? kaleo’s $0 offer for AUVI-Q that covers a majority of the food allergy community?
Probably all of the above. So let’s hope that kaleo resolves these short-term issues as planned and can begin satisfying all hopeful customers.
Before I publish the letter from kaleo’s CEO below, let me ask you to please share your thoughts on the AUVI-Q re-launch and this post in the Comments section. And while I’ve got your attention, remember to click over to the Find Restaurants section of AllergyEats and rate any restaurant experiences you’ve had recently. Each new restaurant rating helps the entire food allergy and intolerance community!
As a company founded by patients with life-threatening allergies, kaleo is grateful for the overwhelming support we have received for AUVI-Q Auto-injector since the product recently returned to the market. Interest in AUVI-Q by patients and healthcare providers has far surpassed all expectations.
The exceptionally high demand for AUVI-Q has resulted in some patients experiencing short-term delays in receiving their prescriptions. To meet the ongoing needs of the community, we took immediate actions by doubling the staff at our call center, temporarily limiting prescriptions to one carton per patient, and implementing a process with guidance from physicians whereby patients who have no epinephrine auto-injector options at home received AUVI-Q first. Most importantly, we have ramped up manufacturing to meet the high demand for AUVI-Q. While we have sufficient manufacturing capacity to supply the entire epinephrine auto-injector market for the United States, there will be a temporary delay in AUVI-Q shipments until we catch up on the inventory demands.
While these measures are being implemented, we believe current production will not be able to address the near-term demand for AUVI-Q. This will result in some patients experiencing delays in receiving AUVI-Q of up to four to six weeks between now and May. This is not a capacity-related inconvenience but rather due to production timing as we build sufficient inventory to clear all backorders and fill new prescriptions. We apologize for the inconvenience this will cause you and your family during this period and appreciate your patience as we work through this temporary situation.
You should consider the following during this temporary delay:
- You can, and should, continue to enroll in the AUVI-Q Direct Delivery Program.
- You will be contacted the same day a prescription is submitted, and in most cases, without 2 hours of the pharmacy network receiving the prescription.
- Delivery of AUVI-Q will be scheduled for the first available shipment, and may be delayed up to 4-6 weeks, between now and May, until the temporary production delays are resolved.
- You are encouraged to ensure there are enough epinephrine auto-injectors on-hand that have not expired until AUVI-Q can arrive and should work with your healthcare provider on alternative options accordingly.
You, your physician or any family member can call our toll-free hotline, 1-877-30-AUVIQ, for updates on your AUVI-Q prescription or to answer questions about how to schedule the delivery date that best suits your needs.
If you have any questions for kaleo, please do not hesitate to contact us. We sincerely apologize for the inconvenience during this period of overwhelming demand for AUVI-Q. We are taking every possible step to continue ramping up production and appreciate your understanding during this temporary period.
President and CEO